OI
NBIX icon

Oakbrook Investments’s Neurocrine Biosciences NBIX Stock Holding History

Oakbrook Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,000
Closed -$215K – 359
2019
Q4 		$215K Sell
2,000
-600
-23% -$62.8K 0.04% 553
2019
Q3 		$234K Sell
2,600
-2,300
-47% -$215K 0.02% 545
2019
Q2 		$414K Buy
4,900
+2,400
+96% +$197K 0.02% 430
2019
Q1 		$220K Buy
+2,500
New +$209K 0.01% 568

Other funds holding NBIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Oakbrook Investments's NBIX Position: Q1 2020 in Review

Oakbrook Investments sold out of Neurocrine Biosciences (NBIX) in Q1 2020, closing a stake of 2,000 shares — an estimated $215K sold.

Oakbrook Investments first reported a position in NBIX in Q1 2019 and held it in 4 quarters. The position peaked at $414K in Q2 2019. 369 funds tracked by Wall St. Rank hold NBIX as of Q1 2020.

  • Oakbrook Investments reported no remaining Neurocrine Biosciences position as of Q1 2020 after selling out during the quarter.
  • Oakbrook Investments sold 2,000 Neurocrine Biosciences shares in Q1 2020, an estimated $215K.
  • Oakbrook Investments first reported a position in Neurocrine Biosciences in Q1 2019 and held it in 4 quarters.
  • Oakbrook Investments's Neurocrine Biosciences position peaked at $414K in Q2 2019.
  • 369 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2020.

Based on Oakbrook Investments's 13F filing for Q1 2020, filed 22 Apr 2020.